Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 12:23pm CEST

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
09:09a ASTRAZENECA : Q1 upbeat on cancer drugs despite Q1 sales drop
08:58a TOP NEWS : AstraZeneca Holds Guidance As Crestor Generics Dent Sales
08:45aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue
08:13a ASTRAZENECA : Q1 2017 Results
08:01a ASTRAZENECA : Q1 2017 Results
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/26 ASTRAZENECA : Tagrisso receives full approval in the EU
04/25 ASTRAZENECA : marks a key milestone with the ‘topping out’ of new gl..
04/25DJASTRAZENECA : Lung Cancer Treatment Approved in EU
04/25 ASTRAZENECA : Gets European Marketing Approval For Tagrisso
More news
Sector news : Pharmaceuticals - NEC
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
08:25a BAYER : CFO Dietsch to leave company in May 2018
08:19aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion
07:56aDJROCHE : Revenue Up 4% at CHF12.94 Billion on Strong Sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/26 Notable earnings before Thursday?s open
04/26 Data readout on AstraZeneca's late-stage lung cancer study of durvalumab exte..
04/26 Lilly Assures Market As Diabetes Stumbles
04/25 5 YEARS IN SEEKING ALPHA'S 'DGI FUN : Mistakes Made, Lessons Learned - And Triu..
04/24 A Physician Analyzes Valeant's Siliq, As The Stock Crashes
Financials ($)
Sales 2017 21 480 M
EBIT 2017 5 823 M
Net income 2017 2 526 M
Debt 2017 12 378 M
Yield 2017 4,53%
P/E ratio 2017 27,06
P/E ratio 2018 22,19
EV / Sales 2017 4,12x
EV / Sales 2018 4,01x
Capitalization 76 157 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 63,1 $
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.20%334 822
ROCHE HOLDING LTD.10.83%223 653
PFIZER INC.3.94%201 581
NOVARTIS AG2.77%201 384
MERCK & CO., INC.6.51%171 894
More Results